Navigation Links
Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
Date:2/17/2011

SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has been shown to reduce and/or block HCV infection in in vitro preclinical models and more recently, has displayed the potential to amplify the effectiveness of existing therapies in difficult to treat HCV-infected patients. This is in addition to CTS-1027's anti-inflammatory and anti-fibrotic effects which have been well established in models of acute hepatitis and liver fibrosis.

"Our previous clinical trials indicate that CTS-1027 used in combination with existing standard-of-care HCV drugs has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by new uninfected liver cells. While reducing HCV virus production in infected cells is extremely important, eliminating HCV-infected cells is crucial to curing HCV," said Dr. Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in combination with the existing standard-of-care drugs as well as the new antiviral drugs under development."

"We have established a collaborative relationship with key opinion leaders and clinical investigators in the hepatitis community," said Ms. MiRa Huyghe, Vice President of Clinical Devel
'/>"/>

SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
2. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
3. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
7. Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
8. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 Migranade, Inc. announced today the ... to the 36 million U.S. migraine sufferers November, 2014. ... targets the actual cause of migraines and not just ... not the source Migranade is assured to be a ... Relief is available at http://www.migranade.com and will ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
(Date:10/30/2014)... CHARLOTTETOWN , Oct. 30, 2014 /CNW/ - Atlantic ... three-year agreement reached between Canada,s ... Jim Keon , President of the Canadian Generic Pharmaceutical ... made the comments while speaking at the Atlantic Summit ... Charlottetown , which is being hosted by the ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... N.J., Aug. 1, 2011 Social stigma is the ... care physicians, according to a survey commissioned by Janssen ... the National Medical Association (NMA).(1) Despite the belief by ... very serious or a crisis in the African-American community, ...
... Reportlinker.com announces that a new market research ... Prefilled Syringes: Devices, Therapeutics, Players, ... http://www.reportlinker.com/p0581168/Prefilled-Syringes-Devices-Therapeutics-Players-Markets-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... continues to grow, the issue of prefilled ...
Cached Medicine Technology:Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 2Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 3Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 4Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 2Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 3
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... have found that an active lifestyle with limiting TV time ... conducted in the US TV watching results in a lower ... games, reading, writing or driving a car. Prolonged TV watching ... are focussed on increasing exercise and hardly concentrate on reducing ...
... whether daily moderate exercise could actually prevent Heart disease. ... hiking, climbing stairs, racket sports and swimming does really ... disease. Recommendations in the United States and elsewhere say ... sufficient for good heart health.// A World Health Organization ...
... that mice lacking a specific immune cell are unable to ... (AHR) which is narrowing of the tiny passages in the ... mite. AHR is triggered by the immune system and leads ... attack. Researchers at Stanford University have been studying mice that ...
... health of their children most expecting moms will do whatever needs ... of rest. But are those moms who smoke, ready to set ... moms willing to put their habit on ,hold for the sake ... recent meeting of the Baxter County Tobacco Control Committee was ,that// ...
... particularly those who are breastfed, should be given vitamin D ... the bones fail to grow straight and strong. While breast ... contain enough vitamin D to meet babies needs. This happens ... of the vitamin D. All infant formula sold in the ...
... now studied a new electrical device,that might lead ... Parkinson's disease.,This new treatment involves implanting an electrical ... for Parkinson's patients. This,electrical device helps stimulate both ... otherwise cause disabling tremor. The researchers ran a ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: